ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AGEN Agenus Inc

0.5607
0.0043 (0.77%)
29 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Agenus Inc AGEN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.0043 0.77% 0.5607 10:45:32
Open Price Low Price High Price Close Price Previous Close
0.5564 0.5505 0.574 0.58 0.5564
more quote information »

Recent News

Date Time Source Heading
14/3/202422:30BWAgenus Reports Fourth Quarter and Full Year 2023 Results
06/3/202423:30BWAgenus Announces Preclinical Data on BMS-986442 (AGEN1777)..
06/3/202408:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
01/3/202408:50EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
29/2/202423:30BWAgenus to Provide Corporate Update and Fourth Quarter & Full..
27/2/202408:24EDGAR2Form DEF 14A - Other definitive proxy statements
26/2/202423:30BWAgenus to Participate in Leerink Partners Global Biopharma..
16/2/202400:02EDGAR2Form PRE 14A - Other preliminary proxy statements
16/2/202400:00EDGAR2Form 8-K - Current report
15/2/202423:02PRNUSGinkgo Bioworks and SaponiQx Awarded MCDC Contract to..
15/2/202400:33EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202423:00EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
10/2/202409:11EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
01/2/202400:00EDGAR2Form 8-K - Current report
31/1/202423:30BWAgenus to Participate in Oppenheimer 34th Annual Healthcare..
23/1/202401:59BWBotensilimab/Balstilimab Breakthrough Data Presented at..
22/1/202423:30BWBotensilimab/Balstilimab Breakthrough Data Presented at..
06/1/202408:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
04/1/202423:30BWAgenus to Participate in B. Riley Healthcare Conference
04/1/202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/12/202323:30BWBotensilimab/Balstilimab Data in Neoadjuvant Colorectal..
11/12/202323:30BWAgenus to Receive $25 Million Milestone Payment from Bristol..
09/12/202308:15EDGAR2Form 8-K - Current report
18/11/202308:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/11/202308:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:30EDGAR2Form 8-K - Current report
07/11/202322:30BWAgenus Reports Third Quarter 2023 Results
27/10/202300:05BWAgenus to Provide Third Quarter 2023 Financial Report and..
23/10/202303:00BWAgenus Unveils New and Updated Botensilimab Data in..
21/10/202319:15BWESMO 2023: Agenus’ Botensilimab/Balstilimab Combination..
17/10/202308:49EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/10/202322:30BWAgenus Completes Enrollment in Randomized Phase 2 Clinical..
07/10/202307:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202322:30BWAgenus To Host BOT/BAL Program Update at ESMO 2023
05/10/202308:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202308:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/10/202308:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/9/202306:30BWAgenus Reports Inducement Grants Under Nasdaq Listing Rule..
01/9/202307:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202307:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/8/202321:30BWAgenus to Participate in September Investor Conferences
23/8/202322:00EDGAR2Form 8-K - Current report
23/8/202322:00BWAgenus Prioritizes Resources to Accelerate Registration and..
09/8/202322:30BWSaponiQx Announces Breakthrough in Scaling Up of STIMULON™..
09/8/202306:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202321:30EDGAR2Form 8-K - Current report
08/8/202321:30BWAgenus Reports Second Quarter 2023 Results
28/7/202321:30BWAgenus Botensilimab/Balstilimab Data Update in Sarcomas..

Your Recent History

Delayed Upgrade Clock